There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exact Sciences (EXAS – Research Report) and Tandem Diabetes Care (TNDM – Research Report) with bullish sentiments.
Tandem Diabetes Care (TNDM)
TD Cowen analyst Josh Jennings maintained a Buy rating on Tandem Diabetes Care today and set a price target of $35.00. The company’s shares closed last Wednesday at $22.55.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of
Currently, the analyst consensus on Tandem Diabetes Care is a Moderate Buy with an average price target of $34.40, a 48.7% upside from current levels. In a report issued on February 16, Lake Street also maintained a Buy rating on the stock with a $60.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EXAS:
- LLY, CVS, EXAS: Which Strong-Buy-Rated Healthcare Stock Is the Better Buy?
- Is EXAS a Buy, Before Earnings?
- BIIB, ZTS, EXAS: Which “Strong Buy” Healthcare Stock is Best?
- Exact Sciences (NASDAQ:EXAS) Announces Strong Preliminary Q4 Results and CFO Transition
- Exact Sciences says Jeff Elliott stepping down as executive VP, CFO
